In general, the genomic changes of these two subtypes are mainly mediated by gene mutations, especially KEAP1, which may contribute to the heterogeneous response of subtypes to tumor treatment, leading to different clinical outcomes. The gene discussed is KEAP1; the disease is neoplasm.